Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Cancer Registry (NCR)

Definition A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives - To measure cancer incidence
- To describe cancer by time, place, persons and disease
- To provide a national database for further epidemiological research
Case definition Target cases are:
- Incident cases by year of diagnosis
- Malignant tumors confirmed by histopathology and/or hematology findings
- Cancers of all sites
Sources of data Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting).
1) The capture system: 
The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms:
- Directly from their clinic; or
- Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients
2) The recapture system: 
The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3).
The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor.
The structure is C##.# M####/##, where:
- C##.# specifies the primary site
- M#### specifies the histology
- /## specifies the behavior and the grade of the tumor
Reporting form NCR reporting form
    ...
    44
    ...
ATC Name B/G Ingredients Dosage Form Price
A04AA01 ZOFRAN INJECTION B Ondansetron (HCl dihydrate) - 8mg/4ml 8mg/4ml Injectable solution 9,752,244 L.L
A10BD07 JANUMET B Metformin HCl - 1000mg, Sitagliptin - 50mg Tablet 3,093,525 L.L
C01BD01 CORDARONE B Amiodarone (HCl) - 200mg 200mg Tablet, scored 349,399 L.L
C09DX01 EXFORGE HCT B Valsartan - 160mg, Amlodipine - 5mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 1,333,092 L.L
G03DA04 UTROGESTAN B Progesterone micronised natural - 100mg 100mg Capsule 525,442 L.L
J02AX04 CANCIDAS B Caspofungin (acetate) - 50mg 50mg Injectable concentrated powder for solution 25,799,521 L.L
L04AD01 SANDIMMUN NEORAL B Ciclosporin - 100mg/ml 100mg/ml Solution 8,264,592 L.L
R03BB04 SPIRIVA WITH HANDIHALER B Tiotropium bromide - 18mcg 18mcg Capsule, inhalation 3,179,531 L.L
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated L.L
D05AX52 DAIVOBET B Calcipotriol - 50mcg/g, Betamethasone - 0.5mg/g Gel 2,100,426 L.L
G03DA04 UTROGESTAN B Progesterone micronised natural - 100mg 100mg Capsule 525,442 L.L
L01CA04 NAVELBINE B Vinorelbine (ditartrate) - 20mg 20mg Capsule, soft gelatin 4,048,997 L.L
L04AD02 PROGRAF 1MG B Tacrolimus - 1mg 1mg Capsule 25,241,922 L.L
M03AC11 NIMBEX B Cisatracurium (besylate) - 20mg/10ml 20mg/10ml Injectable solution 2,010,388 L.L
N02BE01 EFFERALGAN B Paracetamol - 3% 3% Solution 163,949 L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated L.L
C01BD01 CORDARONE B Amiodarone (HCl) - 150mg/3ml 150mg/3ml Injectable concentrated solution 499,909 L.L
C08CA06 NIMOTOP B Nimodipine - 30mg 30mg Tablet, film coated 581,884 L.L
L01CA04 NAVELBINE B Vinorelbine (ditartrate) - 30mg 30mg Capsule, soft gelatin 6,072,824 L.L
L04AD02 PROGRAF 1MG B Tacrolimus - 1mg 1mg Capsule 25,241,922 L.L
M03AC11 NIMBEX B Cisatracurium (besylate) - 20mg/10ml 20mg/10ml Injectable solution 2,010,388 L.L
N02BE01 EFFERALGAN B Paracetamol - 1g 1g Tablet, effervescent 129,009 L.L
N05AH03 ZYPREXA VELOTAB B Olanzapine - 10mg 10mg Tablet, dispersible 5,214,109 L.L
L04AX04 REVLIMID B Lenalidomide - 10mg 10mg Capsule L.L
C01BG11 BRINAVESS B Vernakalant - 20mg/ml 20mg/ml Injectable concentrate for solution 41,821,582 L.L
C08CA08 LUSOPRESS B Nitrendipine - 20mg 20mg Tablet, scored 757,927 L.L
G03DA04 UTROGESTAN B Progesterone micronised natural - 200mg 200mg Capsule 587,259 L.L
J02AX05 MYCAMINE B Micafungin (sodium) - 50mg 50mg Injectable lyophilised powder for solution 13,170,341 L.L
N05AH03 ZYPREXA VELOTAB B Olanzapine - 10mg 10mg Tablet, dispersible 5,214,109 L.L
B02BX05 REVOLADE B Eltrombopag Olamine - 50mg 50mg Tablet, film coated L.L
    ...
    44
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026